FDA Approves Ethiodized Oil Injection for Imaging of Tumors in Adults With Known Hepatocellular Carcinoma
The U.S. Food and Drug Administration has approved ethiodized oil injection (Lipiodol) for selective hepatic intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma. The agent received orphan drug designation for management of patients with known hepatocellular carcinoma in October 2013.
Ethiodized oil, an oil-based radiopaque contrast agent, is also indicated for hysterosalpingography in adults and lymphography in adult and pediatric patients. The agent is contraindicated in patients with hypersensitivity to ethiodized oil, hyperthyroidism, traumatic injuries, recent hemorrhage, or bleeding.
Hepatocellular carcinoma is the most common primary liver tumor and represents the third-leading cause of cancer-related death in the world. An estimated 35,000 patients in the United States were affected by hepatocellular carcinoma in 2013.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
